One commonly used solution to this issue is to select cancer cells that carry the most frequent mutations in the corresponding cancers, such as KRAS for PDAC organoids [21], Wnt and R-spondins for CRC organoids [15, 132], TP53 for GC organoids [43, 44]. This evidence concerns the gene KRAS and gastric cancer.